The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.20
Bid: 7.10
Ask: 7.30
Change: 0.00 (0.00%)
Spread: 0.20 (2.817%)
Open: 7.20
High: 7.20
Low: 7.10
Prev. Close: 7.20
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Close of Tender Offer

6 Feb 2015 12:21

RNS Number : 2925E
Port Erin Biopharma Investments Ltd
06 February 2015
 





For immediate release

6 February 2015

Port Erin Biopharma Investments Limited

 (the "Company")

Close of Tender Offer

On 13 January 2015, Port Erin Biopharma Investments Limited published and sent to shareholders a circular (the "Circular") setting out the terms of a tender offer in respect of a the Company's interest in the Magna Biopharma Income Fund (the "Tender Offer"). The Record Date for the Tender Offer was 1.00 p.m. on 30 January 2015.

On 2 February 2015, the Company further announced that, following expiry of the Record Date, it had received acceptances in respect of up to 17,164,238 shares ("Eligible Shares") of the Company, representing in aggregate, 50.68 per cent. of the issued share capital.

On 30 January 2015, the Company held 324,174.177 Fund Shares (as defined in the Circular). On 5 February 2015 (the Valuation Date), the aggregate holding of Fund Shares was valued at £3,410,637, representing 62.16 per cent. of the Company's net asset value (adjusted for expenses of the Tender Offer) as at 31 December 2014. The Tender Entitlement (as defined in the Circular) of each shareholder accepting the Tender Offer is accordingly set at 62.16 per cent. of Eligible Shares. Accordingly, on completion of the Tender Offer, the Company will redeem and cancel in aggregate 10,669,278 shares (the "Tender Shares").

On 5 February 2015, the Company completed the sale of 116,635.177 Fund Shares (representing 35.98 per cent. of the Company's total holding of Fund Shares), receiving net proceeds of £1,202,269. Thus, the Tender Price (as defined in the Circular) for each Tender Share (taking into account the expenses of the Tender) shall be £0.1587 (15.87 pence). Shareholders who tendered their holdings will therefore retain approx. 37.84 per cent. of their shareholdings and will receive the Tender Price in respect of their remaining holdings which will be cancelled.

After payment of pro rata costs, Mr Mellon and the Mellon Associates shall, on completion of the Tender Offer, be transferred 46,706 Fund Shares by the Company by way of consideration for the tender of 3,095,563 shares of the Company by Mr Mellon and the Mellon Associates. Pursuant to the Tender, Mr Mellon will have disposed of interests in 3,095,563 Ordinary Shares at the Tender Price and will remain interested in 6,729,273 shares representing 29.01 per cent. of the issued shares.

Following completion of the Tender Offer the Company has a total of 23,195,558 issued shares. The figure of 23,195,558 issued shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company, under the FCA's Disclosure and Transparency Rules.

Timetable following Close of the Tender Offer

Cheques in respect of shareholders' Tender Offer consideration, and their revised certificates for their unsold balance holding of shares will be dispatched by not later than 17 February 2015.

CREST Accounts will be credited with shareholders' Tender Offer consideration, and their revised balance holding of shares by not later than 17 February 2015.

 

 

For further information, please contact:

Port Erin Biopharma Investments Limited

Beaumont Cornish Limited

Peterhouse Capital Limited

The Company

Nomad

Broker

Denham Eke

+44 162 463 9396

Roland Cornish

+44 207 628 3396

Lucy Williams

+44 207 469 0930

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTFMTTMBBMBPA
Date   Source Headline
8th Aug 20238:21 amRNSClean Food Group Collaboration with Alianza
2nd Aug 20237:00 amRNSNet Asset Value calculation at 30 June 2023
18th Jul 20239:14 amRNSFormo Successful Tasting Event
18th Jul 20237:00 amRNSFormo Successful Tasting Event
18th Jul 20237:00 amRNSPortfolio Company Update: Galy Co. Update
11th Jul 202311:33 amRNSExercise of Warrants and TVR
22nd Jun 20231:06 pmRNSCultivated Meat Approved for Sale in the US
22nd Jun 202312:42 pmRNSPortfolio Company CellX Raises US$ 6.5 million
22nd Jun 202310:00 amRNSGood Dog Food raises investment from Pets at Home
16th Jun 20237:00 amRNSUSDA Gives First Label Approval to Lab Grown Meat
15th Jun 20237:00 amRNSAUD 2.5 million investment in HydGene Renewables
14th Jun 20237:00 amRNSAgronomics Appoints Comms Consultancy
1st Jun 20237:00 amRNSReplacement Warrant Final Exercise Dates Extension
31st May 20237:00 amRNSExtension of Warrant Final Exercise Dates
9th May 20232:08 pmRNSDirectors' Dealings
4th May 20237:00 amRNSInvestee Company Update: Good Dog Food
2nd May 202311:38 amRNSNet Asset Value calculation as at 31 March 2023
14th Apr 202310:19 amRNSExercise of Warrants and TVR
12th Apr 202312:00 pmRNSInvestee Company Update: Liberation Labs
28th Mar 20237:00 amRNSDirector/PDMR Shareholding
27th Mar 202311:50 amRNSDirector/PDMR Shareholding
16th Mar 20237:00 amRNSFood Fermentation Europe launches
15th Mar 20237:00 amRNSDirectors’ interests in shares
10th Mar 20237:15 amRNSEdison issues update on Agronomics (ANIC)
2nd Mar 20235:50 pmRNSHolding(s) in Company
23rd Feb 20238:00 amRNSANIC invests in Wild Microbes US$3.3m Financing
23rd Feb 20237:00 amRNSAgronomics Welcomes Marisa Drew as a Director
20th Feb 20237:00 amRNSPrecision Fermentation Alliance Formed
9th Feb 20239:00 amRNSAgronomics February 2023 Newsletter
8th Feb 20237:00 amRNSUnaudited Interim Results
7th Feb 20234:49 pmRNSInvestee Company Update: CellX
2nd Feb 202311:04 amRNSResult of AGM
25th Jan 20237:00 amRNSNet Asset Value calculation at 31 December 2022
25th Jan 20237:00 amRNSInvestee company Update: Liberation Labs
4th Jan 20237:00 amRNSPerformance Shares issued to Shellbay Investments
30th Dec 202212:00 pmRNSPortfolio Company Update: Liberation Labs
23rd Dec 20227:00 amRNSSolar Foods receives Euro34 million in grant
20th Dec 20229:00 amRNSFinal Results
5th Dec 20229:18 amRNSInvestee Company Update: Clean Food Group
5th Dec 20227:00 amRNSFurther Investment in Liberation Labs Seed Round
28th Nov 20227:00 amRNSHolding(s) in Company
23rd Nov 20225:59 pmRNSHolding(s) in Company
17th Nov 20227:30 amRNSFirst Cultivated Meat Company gets FDA approval
3rd Nov 20227:00 amRNSAgronomics Capital Markets Day 3rd November
27th Oct 202212:02 pmRNSDirector Dealings
26th Oct 20229:30 amRNSPortfolio Company Solar Foods Update
20th Oct 20227:00 amRNSInvestment in Liberation Labs US$ 20m fundraise
19th Oct 20229:00 amRNSAgronomics October 2022 Newsletter
19th Oct 20227:00 amRNSNet Asset Value calculation to 30 September 2022
12th Oct 20228:53 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.